BioCatalystWatch
RLYBWorkspace / RLYB / OverviewCompany library
Price
Market cap
Next catalystExpected 2H 2027RLYB116 · Phase 2 dataCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

RLYB116

C5 × Albumin

PreINDP1P2P3FilingApproved
RLYB116

C5 × Albumin

Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

RLYB116

C5 × Albumin

Upcoming / outlook

RLYB116

C5 × Albumin

PreINDP1P2P3FilingApproved

Other pipelines

ENPP1

ENPP1

PreINDP1P2P3FilingApproved
RLYB332

Matriptase-2 (MTP-2)

PreINDP1P2P3FilingApproved
RLYB116

C5 × Albumin

RLYB116

C5 × Albumin

RLYB116

C5 × Albumin

PreINDP1P2P3FilingApproved
RLYB331

Matriptase-2 (MTP-2)

RLYB331

Matriptase-2 (MTP-2)

PreINDP1P2P3FilingApproved
REV101

ENPP1

PreINDP1P2P3FilingApproved

Partner / License out

ENPP1

History / paused

HPA-1a

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

RLYB PR & News

RLYB SEC archive